Zenith upcoming events, per their website:
April 29, 2021: Triple Negative Breast Cancer Drug Development Digital Summit 2021
On April 29, 2021, Dr. Eric Campeau will be presenting at the Triple Negative Breast Cancer Drug Development Digital Summit 2021: "Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations." More info can be found HERE
July 15, 2021: Epigenetic Therapeutic Targets
Zenith will be presenting at the Epigenetic Therapeutic Targets digital event on July 15. More info can be found HERE.
"Clinical Development of The BET Bromodomain Inhibitor ZEN-3694 In Solid Tumors: Lessons Learned"
• Design of epigenetic combinatorial therapies
• Clinical activity in breast and prostate cancer patients
• Mechanisms of action: similarities and differences between the prostate
and breast cancer trials
August 19, 2021: Prostate Cancer Drug Development Summit
Zenith will be presenting at the Prostate Cancer Drug Development Summit on August 19, 2021. More info can be found HERE.
"Advance the Development of an Epigenetic-based Therapy in Castration-Resistant Prostate Cancer (CRPC)"
• Explore the combination of the BET bromodomain inhibitor ZEN-3694
with enzalutamide: updated results from the Phase 2a trial
• Discover mechanisms of resistance to enzalutamide targeted
by ZEN-3694
• Examine translational data informing patient pre-selection strategy
